Histone acetyltransferase P300 deficiency promotes ferroptosis of vascular smooth muscle cells by activating the HIF-1α/HMOX1 axis.


Journal

Molecular medicine (Cambridge, Mass.)
ISSN: 1528-3658
Titre abrégé: Mol Med
Pays: England
ID NLM: 9501023

Informations de publication

Date de publication:
06 Jul 2023
Historique:
received: 21 03 2023
accepted: 27 06 2023
medline: 10 7 2023
pubmed: 7 7 2023
entrez: 6 7 2023
Statut: epublish

Résumé

E1A-associated 300-kDa protein (P300), an endogenous histone acetyltransferase, contributes to modifications of the chromatin landscape of genes involved in multiple cardiovascular diseases. Ferroptosis of vascular smooth muscle cells (VSMCs) is a novel pathological mechanism of aortic dissection. However, whether P300 regulates VSMC ferroptosis remains unknown. Cystine deprivation (CD) and imidazole ketone erastin (IKE) were used to induce VSMC ferroptosis. Two different knockdown plasmids targeting P300 and A-485 (a specific inhibitor of P300) were used to investigate the function of P300 in the ferroptosis of human aortic smooth muscle cells (HASMCs). Cell counting kit-8, lactate dehydrogenase and flow cytometry with propidium iodide staining were performed to assess the cell viability and death under the treatment of CD and IKE. BODIPY-C11 assay, immunofluorescence staining of 4-hydroxynonenal and malondialdehyde assay were conducted to detect the level of lipid peroxidation. Furthermore, co-immunoprecipitation was utilized to explore the interaction between P300 and HIF-1α, HIF-1α and P53. Compared with normal control, the protein level of P300 was significantly decreased in HASMCs treated with CD and IKE, which was largely nullified by the ferroptosis inhibitor ferrostatin-1 but not by the autophagy inhibitor or apoptosis inhibitor. Knockdown of P300 by short-hairpin RNA or inhibition of P300 activity by A-485 promoted CD- and IKE-induced HASMC ferroptosis, as evidenced by a reduction in cell viability and aggravation of lipid peroxidation of HASMCs. Furthermore, we found that hypoxia-inducible factor-1α (HIF-1α)/heme oxygenase 1 (HMOX1) pathway was responsible for the impacts of P300 on ferroptosis of HASMCs. The results of co-immunoprecipitation demonstrated that P300 and P53 competitively bound HIF-1α to regulate the expression of HMOX1. Under normal conditions, P300 interacted with HIF-1α to inhibit HMOX1 expression, while reduced expression of P300 induced by ferroptosis inducers would favor HIF-1α binding to P53 to trigger HMOX1 overexpression. Furthermore, the aggravated effects of P300 knockdown on HASMC ferroptosis were largely nullified by HIF-1α knockdown or the HIF-1α inhibitor BAY87-2243. Thus, our results revealed that P300 deficiency or inactivation facilitated CD- and IKE-induced VSMC ferroptosis by activating the HIF-1α/HMOX1 axis, which may contribute to the development of diseases related to VSMC ferroptosis.

Sections du résumé

BACKGROUND BACKGROUND
E1A-associated 300-kDa protein (P300), an endogenous histone acetyltransferase, contributes to modifications of the chromatin landscape of genes involved in multiple cardiovascular diseases. Ferroptosis of vascular smooth muscle cells (VSMCs) is a novel pathological mechanism of aortic dissection. However, whether P300 regulates VSMC ferroptosis remains unknown.
METHODS METHODS
Cystine deprivation (CD) and imidazole ketone erastin (IKE) were used to induce VSMC ferroptosis. Two different knockdown plasmids targeting P300 and A-485 (a specific inhibitor of P300) were used to investigate the function of P300 in the ferroptosis of human aortic smooth muscle cells (HASMCs). Cell counting kit-8, lactate dehydrogenase and flow cytometry with propidium iodide staining were performed to assess the cell viability and death under the treatment of CD and IKE. BODIPY-C11 assay, immunofluorescence staining of 4-hydroxynonenal and malondialdehyde assay were conducted to detect the level of lipid peroxidation. Furthermore, co-immunoprecipitation was utilized to explore the interaction between P300 and HIF-1α, HIF-1α and P53.
RESULTS RESULTS
Compared with normal control, the protein level of P300 was significantly decreased in HASMCs treated with CD and IKE, which was largely nullified by the ferroptosis inhibitor ferrostatin-1 but not by the autophagy inhibitor or apoptosis inhibitor. Knockdown of P300 by short-hairpin RNA or inhibition of P300 activity by A-485 promoted CD- and IKE-induced HASMC ferroptosis, as evidenced by a reduction in cell viability and aggravation of lipid peroxidation of HASMCs. Furthermore, we found that hypoxia-inducible factor-1α (HIF-1α)/heme oxygenase 1 (HMOX1) pathway was responsible for the impacts of P300 on ferroptosis of HASMCs. The results of co-immunoprecipitation demonstrated that P300 and P53 competitively bound HIF-1α to regulate the expression of HMOX1. Under normal conditions, P300 interacted with HIF-1α to inhibit HMOX1 expression, while reduced expression of P300 induced by ferroptosis inducers would favor HIF-1α binding to P53 to trigger HMOX1 overexpression. Furthermore, the aggravated effects of P300 knockdown on HASMC ferroptosis were largely nullified by HIF-1α knockdown or the HIF-1α inhibitor BAY87-2243.
CONCLUSION CONCLUSIONS
Thus, our results revealed that P300 deficiency or inactivation facilitated CD- and IKE-induced VSMC ferroptosis by activating the HIF-1α/HMOX1 axis, which may contribute to the development of diseases related to VSMC ferroptosis.

Identifiants

pubmed: 37415103
doi: 10.1186/s10020-023-00694-7
pii: 10.1186/s10020-023-00694-7
pmc: PMC10324182
doi:

Substances chimiques

Heme Oxygenase-1 EC 1.14.14.18
HMOX1 protein, human EC 1.14.14.18
Hypoxia-Inducible Factor 1, alpha Subunit 0
Tumor Suppressor Protein p53 0
EP300 protein, human EC 2.3.1.48
HIF1A protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

91

Subventions

Organisme : National Natural Science Foundation of China
ID : 82170502
Organisme : National Natural Science Foundation of China
ID : 82070488
Organisme : Nature Science Foundation of Hubei Province project
ID : 2022CFB291

Informations de copyright

© 2023. The Author(s).

Références

Biochim Biophys Acta Mol Basis Dis. 2020 Oct 1;1866(10):165836
pubmed: 32413386
Am J Physiol Heart Circ Physiol. 2020 Mar 1;318(3):H508-H518
pubmed: 31975626
Trends Biochem Sci. 2016 Aug;41(8):700-711
pubmed: 27283514
Exp Mol Med. 2004 Feb 29;36(1):1-12
pubmed: 15031665
Am J Physiol Lung Cell Mol Physiol. 2014 Mar 15;306(6):L543-51
pubmed: 24441870
J Thorac Cardiovasc Surg. 2008 Jul;136(1):65-72, 72.e1-3
pubmed: 18603055
Cell Prolif. 2022 Jan;55(1):e13158
pubmed: 34811833
Kidney Int. 2022 Dec;102(6):1259-1275
pubmed: 36063875
Nature. 2017 Oct 5;550(7674):128-132
pubmed: 28953875
Pharmacol Res. 2022 Mar;177:106122
pubmed: 35149187
Biomed Pharmacother. 2019 Dec;120:109567
pubmed: 31670031
J Neurochem. 2005 Sep;94(5):1288-96
pubmed: 16000154
Front Cardiovasc Med. 2022 Apr 14;9:833642
pubmed: 35498043
Mol Med. 2022 Oct 3;28(1):121
pubmed: 36192693
Cell Biosci. 2017 Oct 10;7:52
pubmed: 29051813
Int J Biol Sci. 2020 Feb 10;16(7):1252-1263
pubmed: 32174799
Cells. 2021 Sep 13;10(9):
pubmed: 34572050
Cancer Med. 2018 Aug;7(8):4012-4022
pubmed: 29989329
Redox Biol. 2022 Jun;52:102312
pubmed: 35447413
MedComm (2020). 2023 May 22;4(3):e267
pubmed: 37229485
Front Endocrinol (Lausanne). 2021 Feb 18;12:626390
pubmed: 33679620
Epigenetics. 2017;12(11):1004-1013
pubmed: 28933600
Cancer Med. 2013 Oct;2(5):611-24
pubmed: 24403227
eNeuro. 2019 Feb 15;6(1):
pubmed: 30783618
Exp Mol Pathol. 2021 Jun;120:104642
pubmed: 33905708
Mol Med. 2017 Oct;23:196-203
pubmed: 28805231
Circulation. 2022 Jun 7;145(23):1720-1737
pubmed: 35502657
J Immunol. 2006 Jan 1;176(1):451-62
pubmed: 16365438
Int J Biol Sci. 2022 Jun 21;18(10):4118-4134
pubmed: 35844806
Cell Rep. 2017 Aug 15;20(7):1692-1704
pubmed: 28813679
Pharmacol Res. 2022 Feb;176:106048
pubmed: 34968685
Cell Death Dis. 2018 Feb 7;9(2):180
pubmed: 29416002
Mol Med. 2019 Mar 29;25(1):10
pubmed: 30925865
Cell Death Dis. 2023 Mar 21;14(3):205
pubmed: 36944609
Cell Death Dis. 2019 Jan 28;10(2):81
pubmed: 30692512
Prostate. 2011 Mar 1;71(4):431-7
pubmed: 20859991
Oxid Med Cell Longev. 2019 Sep 2;2019:3201062
pubmed: 31565149
Antioxidants (Basel). 2023 Jan 31;12(2):
pubmed: 36829885
Am J Transl Res. 2016 Jan 15;8(1):37-48
pubmed: 27069538
J Hazard Mater. 2022 Mar 15;426:127807
pubmed: 34863575
Nucleic Acids Res. 2019 Nov 4;47(19):10212-10234
pubmed: 31538203
Oncol Lett. 2023 Jan 19;25(3):90
pubmed: 36817050
J Clin Invest. 2018 Aug 1;128(8):3341-3355
pubmed: 29939160
Cell Death Dis. 2022 Jun 6;13(6):530
pubmed: 35668064
Oxid Med Cell Longev. 2020 Nov 26;2020:8832043
pubmed: 33294126

Auteurs

Juan Shi (J)

Division of Cardiothoracic and Vascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, 430030, Wuhan, Hubei, China.

Qun-Hui Wang (QH)

Division of Cardiothoracic and Vascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, 430030, Wuhan, Hubei, China.

Xiang Wei (X)

Division of Cardiothoracic and Vascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, 430030, Wuhan, Hubei, China.
Key Laboratory of Organ Transplantation, Ministry of Education; NHC Key Laboratory of Organ Transplantation; Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, Hubei, China.

Bo Huo (B)

Division of Cardiothoracic and Vascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, 430030, Wuhan, Hubei, China.

Jian-Nan Ye (JN)

Division of Cardiothoracic and Vascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, 430030, Wuhan, Hubei, China.

Xin Yi (X)

Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.

Xin Feng (X)

Division of Cardiothoracic and Vascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, 430030, Wuhan, Hubei, China.

Ze-Min Fang (ZM)

Division of Cardiothoracic and Vascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, 430030, Wuhan, Hubei, China.

Ding-Sheng Jiang (DS)

Division of Cardiothoracic and Vascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, 430030, Wuhan, Hubei, China. jds@hust.edu.cn.
Key Laboratory of Organ Transplantation, Ministry of Education; NHC Key Laboratory of Organ Transplantation; Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, Hubei, China. jds@hust.edu.cn.

Ming-Jia Ma (MJ)

Division of Cardiothoracic and Vascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, 430030, Wuhan, Hubei, China. mamingjia1984@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH